SAN DIEGO, Dec. 16, 2025 /PRNewswire/ -- Shareholders Foundation, Inc. announced that a lawsuit is pending for certain investors in Neogen Corporation (NASDAQ: NEOG) shares. Investors who purchased shares of Neogen Corporation prior to January 2023 and continue to hold any of thoseNASDAQ: NEOG shares also have certain options and contact the Shareholders Foundation at [email protected] or call +1(858) 779 - 1554. On July 18, 2025, aNASDAQ:NEOG investor filed a lawsuit over alleged securities laws violation ...

U.S. stock futures were lower this morning, with the Dow futures falling around 0.2% on Tuesday.Shares of Lightwave Logic Inc (NASDAQ:LWLG) fell sharply in pre-market trading after the company announced pricing of $35 million public offering of common stock.Lightwave Logic shares dipped 14.5% to $3.22 in pre-market trading.Here are some other stocks moving lower in pre-market trading.Ascent Solar Technologies, Inc. (NASDAQ:ASTI) shares dipped 15.1% to $3.54 in pre-market trading after jumping 34% on Monday. ...

U.S. stock futures were lower this morning, with the Dow futures falling around 0.2% on Tuesday.Shares of Lightwave Logic Inc (NASDAQ:LWLG) fell sharply in pre-market trading after the company announced pricing of $35 million public offering of common stock.Lightwave Logic shares dipped 14.5% to $3.22 in pre-market trading.Here are some other stocks moving lower in pre-market trading.Ascent Solar Technologies, Inc. (NASDAQ:ASTI) shares dipped 15.1% to $3.54 in pre-market trading after jumping 34% on Monday. ...

Key Takeaways Neogen sees gains from product launches, Animal Safety demand and progress on 3M Food Safety integration.NEOG highlights growth across biologics, wound care, substrates, reagents and insect control products.Neogen faces high debt, macro pressures and expects a $10M annualized impact from steep U.S. tariff rates.Neogen Corporation (NEOG) is well-poised to gain in the coming quarters, thanks to its continued product development efforts that enhance its existing offerings and advance its business ...

We came across a bullish thesis on Neogen Corporation on Valueinvestorsclub.com by Dr. Ridgewell. In this article, we will summarize the bulls’ thesis on NEOG. Neogen Corporation's share was trading at $5.92 as of December 1st. NEOG’s trailing and forward P/E were 822.50 and 16.00 respectively according to Yahoo Finance. Soleno Therapeutics (SLNO) Jumps 13.46% as Competitor Fails Prader-Willi Treatment Trial Romaset/Shutterstock.com Neogen presents a compelling opportunity to invest in a high-quality fo ...

Core Viewpoint - Neogen (NEOG) shares have increased by 11.7% in the past four weeks, closing at $6.29, with a potential upside indicated by Wall Street analysts' price targets suggesting a mean estimate of $8.17, representing a 29.9% upside [1] Price Targets - The average price targets range from a low of $6.50 to a high of $10.00, with a standard deviation of $1.76, indicating variability among analysts [2] - The lowest estimate suggests a 3.3% increase, while the highest estimate indicates a 59% upside [2] Analyst Consensus and Earnings Estimates - Analysts show a strong agreement in revising earnings estimates higher, which historically correlates with stock price movements [4][11] - The Zacks Consensus Estimate for the current year has increased by 50% over the past month, with no negative revisions [12] - NEOG holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] Caution on Price Targets - While price targets are commonly referenced, they can mislead investors, as empirical research shows they rarely indicate actual stock price movements [7][10] - Analysts may set overly optimistic price targets due to business incentives, which can inflate expectations [8]

Core Viewpoint - Kuehn Law, PLLC is investigating potential breaches of fiduciary duties by certain officers and directors of Neogen Corporation related to misrepresentation of the 3M integration status and undisclosed negative impacts on financial health [1]. Group 1 - Kuehn Law is specifically looking into allegations that insiders at Neogen misrepresented the status of the 3M integration [1]. - The investigation is based on a federal securities lawsuit that claims the failure to disclose integration issues has negatively affected Neogen's financial health [1]. Group 2 - Shareholders who purchased NEOG shares prior to January 5, 2023, are encouraged to contact Kuehn Law for potential legal action [2]. - Kuehn Law covers all case costs and does not charge its investor clients, emphasizing the importance of timely action for shareholders [2]. Group 3 - The firm highlights the significance of shareholder participation in maintaining the integrity and fairness of financial markets [3]. - Kuehn Law promotes the idea that every shareholder's voice contributes to their investment future [3].

Core Insights - Neogen (NASDAQ: NEOG) is undergoing a divestment to reduce leverage due to poor performance and debt concerns [1] Group 1: Company Performance - Neogen has been struggling with its business performance, which has been impacted by a debt overhang [1] Group 2: Corporate Events - The investing group "Value In Corporate Events" focuses on major corporate events such as IPOs, mergers & acquisitions, and earnings reports to identify investment opportunities [1]

Core Insights - Neogen Corporation (NEOG) reported first-quarter fiscal 2026 adjusted earnings per share (EPS) of 4 cents, missing the Zacks Consensus Estimate by 20% and reflecting a 42.9% decline from the previous year [1][10] - Revenues for the quarter decreased 3.6% year-over-year to $209.2 million, with core revenues increasing by 0.3% [2][10] - Following the earnings announcement, NEOG stock rose by 16.5% to close at $6.78 [2] Revenue Breakdown - The Food Safety segment generated revenues of $152.1 million, a 4.6% decrease year-over-year, with a core revenue decline of 1.7% [3][4] - The Animal Safety segment reported revenues of $57.1 million, down 0.8% year-over-year, but core revenues increased by 5.8% [5] - The Genomics business returned to positive core revenue growth in the mid-single-digit range [6] Margin and Expense Analysis - Gross profit declined 9.5% year-over-year to $95 million, with gross margin contracting by 296 basis points to 45.4% [7] - Sales and marketing expenses were $45 million, down 1.6% year-over-year, while administrative expenses increased by 17.8% to $61 million [8] Cash Position and Liabilities - Neogen's cash and cash equivalents at the end of the first quarter totaled $138.9 million, up from $129 million at the end of the previous quarter [9] - The company has total outstanding debt of $800 million and a committed borrowing headroom of $201.5 million [9] Fiscal 2026 Outlook - Neogen reaffirmed its fiscal 2026 revenue projections of $820-$840 million, with adjusted EBITDA expected to be between $165 million and $175 million [11][10] - Capital expenditures are projected to be around $50 million [11] Performance Summary - The company ended the first quarter with mixed results, as earnings missed expectations while revenues exceeded estimates [12] - Execution challenges have impacted performance, but the company is focusing on commercial excellence and cost structure improvements [12][13]

Core Insights - Neogen Corp. reported better-than-expected first-quarter sales results, leading to a stock rally [1][4] - Analysts from William Blair noted transient issues affecting performance but expect improvements in the future [2] - The company reaffirmed its fiscal 2026 sales guidance of $820 million to $840 million, slightly above consensus estimates [3] Financial Performance - First-quarter adjusted earnings were 4 cents per share, aligning with estimates, while sales reached $209.19 million, down 3.6% year-over-year but exceeding consensus of $204.16 million [5] - Gross margin for Q1 was 45.4%, down from 48.4% a year ago, attributed to production relocation and lower revenue [5] - Adjusted EBITDA for the first quarter was $35.5 million, with an adjusted EBITDA margin of 17.0%, compared to $43.7 million and a margin of 20.1% in the previous year [5] Segment Performance - Food Safety segment revenues were $152.1 million, a decrease of 4.6%, with growth in pathogen detection products [6] - Animal Safety segment sales were $57.1 million, a slight decrease of 0.8%, driven by higher sales in biologics and wound care [6] - Genomics segment returned to positive core revenue growth in the mid-single-digit range, despite a decline in the companion animal market [6]